This guide provides practical, evidence-based information that first responder agencies, their partners, and communities can use to implement or expand practices and programs for linking people to substance use services.

This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This TIP supports learning about the key aspects, functions, and uses of Peer Support Services (PSS) in recovery from problematic substance use, which will help providers, supervisors, and administrators in SUD treatment programs better understand and respond to these changes.

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

This advisory introduces readers to cannabidiol (CBD), how it is derived, and how it differs from delta-9 THC and other cannabinoids. The advisory focuses on the risks and harms of CBD, especially those sold over the counter. This advisory also clarifies common misconceptions about CBD, given its broad availability and marketing for several medical conditions despite limited evidence of efficacy.

This guide highlights strategies for behavioral health and housing providers to conduct outreach and engage with individuals experiencing homelessness, initiate use of behavioral health treatment as they wait to receive stable housing and retain them in their recovery efforts once housed.

This guide reviews interventions for people living with substance use and mental disorders who are at risk for or living with HIV. Selected interventions are in alignment with goals of the federal “Ending the HIV Epidemic: A Plan for America” (EHE) initiative.

This guide supports health care providers, systems, and communities seeking to prevent vaping. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This guide supports health care providers, systems, and communities seeking to treat stimulant use disorders. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This guide focuses on using medication-assisted treatment for opioid use disorder in jails and prisons and during the reentry process when justice-involved persons return to the community. It provides an overview of policies and evidence-based practices that reduce the risk of overdose and relapse.

The Rx Pain Medications, Know the Options, Get the Facts is a series of 13 fact sheets designed to increase awareness of the risks associated with prescription opioid use and misuse, as well as to educate patients who are prescribed opioids for pain about the risks and to provide resources on methods for alternative pain management.

This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD

This fact sheet developed by CDC’s National Institute for Occupational Safety and Health (NIOSH) helps employers understand the risk of opioid overdose and allows them to decide if they should establish a workplace naloxone availability and use program.

This Harm Reduction Coalition (HRC) manual outlines the process of developing an Overdose Prevention and Education Program, with or without a take-home naloxone component. Such a program may be integrated into existing services for people affected by substance abuse, including shelter and supportive housing agencies, treatment programs, parent and student groups, and communities at-large.

This guide from the American Society of Addiction Medicine (ASAM) includes information on assessment, treatment overview (including treatment plans, patient participation, and counseling), and all the medications available to treat opioid use and overdose. It also provides links to find a provider and support groups for patients and families.